Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Growth Metrics

Guided Therapeutics (GTHP) Long-Term Investments (2025)

Guided Therapeutics' Long-Term Investments history spans 1 years, with the latest figure at $472502.0 for Q4 2025.

On a quarterly basis, Long-Term Investments changed N/A to $472502.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $472502.0, a N/A change, with the full-year FY2025 number at $472502.0, changed N/A from a year prior.
Long-Term Investments hit $472502.0 in Q4 2025 for Guided Therapeutics.
Over the last five years, Long-Term Investments for GTHP hit a ceiling of $472502.0 in Q4 2025 and a floor of $472502.0 in Q4 2025.